SCHEMBL25895223

SCHEMBL25895223

CC(C)C(=O)N1CCC(C(=O)N(C)C(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 2/20 0.40
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37
CHRNB3 Q05901 1/20 0.37
CHRNA6 Q15825 1/20 0.37
NPY5R Q15761 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
DPP4 P27487 1/20 0.35
KCNH2 Q12809 1/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25895221 0.90 MEN1 (0.40) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL19652201 0.86 MEN1 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL25895224 0.82 CHRNB2 (0.47) MEN1KMT2ASMN1; SMN2CHRNB2CHRNA3
SCHEMBL23342020 0.81 CHRNB2 (0.37) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL18389965 0.80 MEN1 (0.38) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL25920032 0.80 GAA (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL23342773 0.80 GAA (0.46) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL23342149 0.80 HPGD (0.36) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL12375166 0.79 HSD11B1 (0.37) MEN1KMT2ASMN1; SMN2DPP4KCNH2
SCHEMBL22481553 0.79 ALDH1A1 (0.53) MEN1KMT2ASMN1; SMN2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739074-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-08-29 US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11739074-B2 Ras inhibitors KRAS, NRAS, HRAS MEN1 340/4885KMT2A 3873/4885SMN1; SMN2 3861/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR MEN1 2520/4885KMT2A 3021/4885SMN1; SMN2 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.